Tagged with Reimbursement,

Switzerland’s Upcoming Cost Containment Packages: Industry Key Concerns
China’s National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Market Access in Switzerland: Reimbursement Delays for 76% of New Products Undermining Innovation Reputation
Overcoming US Pricing & Reimbursement Challenges
Mattias Bankel – General Manager, Head of Nordics & Baltics, Amicus Therapeutics
Chinese PD-1 Cancer Drugs: Global Competition for Big Pharma
Forging a New Path to Commercialization for Cell and Gene Therapies
Shooting For the Stars: The Evolution in Outcome-Based Payment Models for Medicines
Adriano Antonio Treve – General Manager, Roche Turkey
Interview: Andrejs Pantelejevs – Head of Bureau, Ministry of Health, Latvia
Interview: Kuuno Vaher – Market Access Director Baltics and Country Lead AstraZeneca Estonia
Interview: Wojciech Koziejowski – Managing Director, Lundbeck Poland
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here